Connect Biopharma Holdings Ltd (NASDAQ:CNTB) — Market Cap & Net Worth
Market Cap & Net Worth: Connect Biopharma Holdings Ltd (CNTB)
Connect Biopharma Holdings Ltd (NASDAQ:CNTB) has a market capitalization of $57.07 Million ($57.07 Million) as of October 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21349 globally and #4801 in its home market, demonstrating a -4.08% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Connect Biopharma Holdings Ltd's stock price $0.91 by its total outstanding shares 62974309 (62.97 Million).
Connect Biopharma Holdings Ltd Market Cap History: 2021 to 2026
Connect Biopharma Holdings Ltd's market capitalization history from 2021 to 2026. Data shows change from $324.32 Million to $57.07 Million (-41.76% CAGR). Check CNTB stock price for real-time trading data and today's change.
Index Memberships
Connect Biopharma Holdings Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #607 of 976 |
|
NASDAQ Composite
IXIC
|
$42.05 Trillion | 0.00% | #2031 of 3165 |
Weight: Connect Biopharma Holdings Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Connect Biopharma Holdings Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Connect Biopharma Holdings Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see cash flow conversion of Connect Biopharma Holdings Ltd for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
2774.81x
Connect Biopharma Holdings Ltd's market cap is 2774.81 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $86.90 Million | $26.03 Million | -$15.63 Million | 3.34x | N/A |
| 2025 | $177.59 Million | $64.00K | -$55.48 Million | 2774.81x | N/A |
Competitor Companies of CNTB by Market Capitalization
Companies near Connect Biopharma Holdings Ltd in the global market cap rankings as of October 16, 2026. See Connect Biopharma Holdings Ltd net asset quality index to understand what proportion of total assets are financed by equity.
Key companies related to Connect Biopharma Holdings Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #184 globally with a market cap of $128.95 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #439 globally with a market cap of $64.16 Billion USD ( AU$90.67 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #507 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #184 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.95 Billion | $508.75 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $796.34 |
| #439 | CSL Ltd | AU:CSL | $64.16 Billion | AU$186.90 |
| #507 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $236.50 |
Connect Biopharma Holdings Ltd Historical Marketcap From 2021 to 2026
Between 2021 and today, Connect Biopharma Holdings Ltd's market cap moved from $324.32 Million to $ 57.07 Million, with a yearly change of -41.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $57.07 Million | -67.87% |
| 2025 | $177.59 Million | +104.35% |
| 2024 | $86.90 Million | +16.95% |
| 2023 | $74.31 Million | +35.98% |
| 2022 | $54.65 Million | -83.15% |
| 2021 | $324.32 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 16th, 2026 the market cap of Connect Biopharma Holdings Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $57.07 Million USD |
| MoneyControl | $57.07 Million USD |
| MarketWatch | $57.07 Million USD |
| marketcap.company | $57.07 Million USD |
| Reuters | $57.07 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.